Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Jul 19, 2022 10:03pm
169 Views
Post# 34836035

RE:RE:RE:RE:RE:Question

RE:RE:RE:RE:RE:Question

Agree with your thesis, except the last three words. 


Maintaining too low of a share price for too long has watered down the ultimate ROI to every long term holder ( still nice if we're right, but could have been much higher  for all with perhaps 100 million fewer shares o/s) 

insiders have lower risk with more knowledge, they can more safely accumulate, and often at zero cost until certainty is achieved ( eg via options, warrants, psu's, dsu's, etc) 

outside retailers have to guess as to progress, put more skin in the game at all times, and hold their nose and invest somewhat blindly or on faith, in the event of dilutive financings. 


if you redo the math but assume that only 200million shares were issued ( fully diluted) , your ultimate share target price would be higher by 50%. 


MM 

<< Previous
Bullboard Posts
Next >>